Short-term surgical outcomes of robotic gastrectomy. A single center/single surgeon experience

Surgical resection is considered the optimum approach to the treatment of gastric cancer. The present study evaluates the efficacy of robotic surgery for the treatment of gastric cancer.

Included in the study were 30 patients who underwent robotic surgery for gastric cancer at the General Surgery Clinic between July 2021 and 2022. The demographic and clinical properties of the patients,intraoperative and postoperative results, tumor Characteristics, and early morbidity and mortality values were evaluated.

The mean age of the 30 (F/M:8/22) patients was 63.9 (42-83) years, among which 20 (66.7%) had undergone neoadjuvant treatment. The mean surgery duration was 252.82 (110-380) minutes. A subtotal gastrectomy was performed in 10 patients (33%), while the remaining 20 patients (67%) underwent a total gastrectomy. The operation was converted to open surgery in four patients (13.2%). No intraoperative complications were seen, although one patient (3%) underwent re-anastomosis on postoperative day 3 due to an obstruction in the gastroenterostomy anastomosis. The mean largest diameter of the tumor was 4.6 (0-9) cm; the mean number of resected lymph nodes was 30.8 (11-58); and the mean duration of hospital stay was 5.9 (3-12) days. Early mortality within the first 30 days was seen in one patient with a cardiac cause. The rate of re-admission to hospital within the first 90 days was 11% (3 patients).

Robotic surgery in patients with gastric cancer can be applied efficiently considering the successful clinicopathological results, short hospital stay, and low morbidity and mortality rates.

Cancer, Morbidity, Mortality, Robotic Surgery, Stomach.